<DOC>
	<DOCNO>NCT03091595</DOCNO>
	<brief_summary>A combined oral contraceptive ( COC ) contain 15 mg E4 3 mg DRSP administer 24 day follow 4 placebo tablet , evaluate development . This study investigate effect COC ovarian function inhibition , level serum luteinizing hormone ( LH ) , follicle-stimulating hormone ( FSH ) , estradiol ( E2 ) progesterone 3 treatment cycle comparison reference COC 20 mcg EE/3 mg DRSP .</brief_summary>
	<brief_title>E4/DRSP Ovarian Function Inhibition Study</brief_title>
	<detailed_description />
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Overtly healthy female subject , determine medical history , physical examination include breast examination , gynecological examination ( include cervical smear [ Pap smear ] ) , vital sign , ECG , echocardiogram , laboratory test . Negative pregnancy test subject screening . Women ovulate PreTreatment Cycle . Willing use nonhormonal method contraception ( e.g . condom ) washout period , PreTreatment Cycle PostTreatment Cycle . BMI 18.0 35.0 kg/mÂ² , inclusive , time Screening . Able fulfill requirement protocol indicated willingness participate study provide write informed consent form ( ICF ) . Irregular menstrual cycle . Amenorrhea abnormal uterine bleeding . Clinically relevant abnormal laboratory result Screening . Clinically significant abnormality uterus and/or ovary detect examination and/or ultrasound . Known hypersensitivity investigational reference product ingredient . Intention become pregnant course study . Pregnancy accurate hormonal contraceptive use past . Dyslipoproteinemia require active treatment antilipidemic agent . Diabetes mellitus vascular involvement ( nephropathy , retinopathy , neuropathy , ) diabetes mellitus 20year duration . Any arterial hypertension . Any condition associate increase risk venous thromboembolism and/or arterial thromboembolism . Complicated valvular heart disease . History pregnancyrelated cardiomyopathy moderately severely impaired cardiac function . Systemic lupus erythematosus . Presence history migraine aura . Abnormal Papanicolaou ( PAP ) smear result . Presence undiagnosed breast mass . Current symptomatic gallbladder disease . History COCrelated cholestasis . Presence history severe hepatic disease . Presence history pancreatitis associate hypertriglyceridemia . Porphyria . Presence history hepatocellular adenoma malignant liver tumor . Renal impairment . Hyperkaliemia presence condition predispose hyperkaliemia . Presence history hormonerelated malignancy . History nonhormonerelated malignancy within 5 year Screening . Subjects nonmelanoma skin cancer allow study . Use drug potentially trigger interaction COCs . History alcohol drug abuse . Any prior procedure , disease condition could result altered absorption , excessive accumulation , impaired metabolism , altered excretion investigational product . Uncontrolled thyroid disorder . Have receive investigational drug within last 2 cycle prior start PreTreatment Cycle . Subjects participate oral contraceptive clinical study , use Food Drug Administration ( FDA ) /European Union ( EU ) approve active ingredient , may start PreTreatment Cycle one cycle last medication intake precede study . Sponsor , contract research organization ( CRO ) PI 's site personnel directly affiliate study . Is judged PI unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>